# IL-18-Mediated Tumor Immune Evasion

**Authors:** Shuai Li, Chenxia Gao, Hongyu Zhao, Didi Wang, Shuang Liu

PMC · DOI: 10.3390/cimb48020202 · Current Issues in Molecular Biology · 2026-02-12

## TL;DR

This paper reviews how IL-18 influences tumor immune evasion and explores its role in cancer progression and treatment strategies.

## Contribution

The paper systematically reviews the context-dependent roles of IL-18 in tumor immune evasion and proposes new precision treatment strategies.

## Key findings

- IL-18 acts as a context resistor in tumor progression, influenced by cancer type and tumor microenvironment.
- Regulation of IL-18 offers potential for reducing tumor immune escape in cancer treatment.
- Heterogeneity patterns of IL-18 effects highlight challenges in clinical translation.

## Abstract

Immune response evasion is one of the hallmark features of cancer, which is not only the basis for cancer progression and metastasis but also affects the clinical management of cancer. Tumor immune evasion is mainly attributed to the dynamic and immunosuppressive tumor microenvironment (TME), which is regulated by a complex system including immunosuppressive cells and cytokines. Interleukin-18 (IL-18) is an important cytokine that plays a multifaceted role in immune system regulation, and its function is strictly regulated by the natural antagonist IL-18 binding protein (IL-18BP). IL-18 exhibits context-dependent immunoregulatory characteristics (acting as a “context resistor”) during tumor occurrence and progression, which is closely related to cancer type, stage, and the signaling network of the tumor microenvironment. The multifaceted functions of IL-18 have been utilized in cancer treatment to reduce the phenomenon of immune escape of tumors. With the latest advancements in cancer research related to IL-18, it is necessary to integrate the latest research findings to deepen the understanding of the mechanism of tumor immune escape and promote the improvement of cancer treatment levels. This review will systematically elaborate on the action mode, core regulatory mechanism and key signaling pathways of IL-18 in tumor immune evasion, analyze the heterogeneity patterns associated with its context-dependent effects, comprehensively sort out the core obstacles in clinical translation, and at the same time, envision new precision treatment strategies based on IL-18 regulation.

## Linked entities

- **Proteins:** IL18 (interleukin 18), IL18BP (interleukin 18 binding protein)

## Full-text entities

- **Genes:** Ifng (interferon gamma) [NCBI Gene 15978] {aka IFN-g, If2f, Ifg}, LGALS9 (galectin 9) [NCBI Gene 3965] {aka HUAT, LGALS9A}, NFKB1 (nuclear factor kappa B subunit 1) [NCBI Gene 4790] {aka CVID12, EBP-1, KBF1, NF-kB, NF-kB1, NF-kappa-B1}, CXCL8 (C-X-C motif chemokine ligand 8) [NCBI Gene 3576] {aka GCP-1, GCP1, IL8, LECT, LUCT, LYNAP}, Mmp2 (matrix metallopeptidase 2) [NCBI Gene 17390] {aka Clg4a, GelA, MMP-2}, IL12B (interleukin 12B) [NCBI Gene 3593] {aka CLMF, CLMF2, IL-12B, IMD28, IMD29, NKSF}, VEGFA (vascular endothelial growth factor A) [NCBI Gene 7422] {aka L-VEGF, MVCD1, VEGF, VPF}, Il18 (interleukin 18) [NCBI Gene 16173] {aka Igif, Il-18}, IL18 (interleukin 18) [NCBI Gene 3606] {aka IGIF, IL-18, IL-1g, IL1F4}, LAMP1 (lysosome associated membrane protein 1) [NCBI Gene 3916] {aka CD107a, LAMPA, LGP120}, IL18R1 (interleukin 18 receptor 1) [NCBI Gene 8809] {aka CD218a, CDw218a, IL-18R, IL-18R-alpha, IL-18Ralpha, IL-1Rrp}, IL10 (Interleukin 10 level) [NCBI Gene 103158318], Pik3r1 (phosphoinositide-3-kinase regulatory subunit 1) [NCBI Gene 18708] {aka PI3K, p50alpha, p55alpha, p85alpha}, TNF (tumor necrosis factor) [NCBI Gene 7124] {aka DIF, IMD127, TNF-alpha, TNFA, TNFSF2, TNLG1F}, IL10 (interleukin 10) [NCBI Gene 3586] {aka CSIF, GVHDS, IL-10, IL10A, TGIF}, STAT3 (signal transducer and activator of transcription 3) [NCBI Gene 6774] {aka ADMIO, ADMIO1, APRF, HIES}, AKT1 (AKT serine/threonine kinase 1) [NCBI Gene 207] {aka AKT, PKB, PKB-ALPHA, PRKBA, RAC, RAC-ALPHA}, HAVCR2 (hepatitis A virus cellular receptor 2) [NCBI Gene 84868] {aka CD366, HAVcr-2, KIM-3, SPTCL, TIM3, TIMD-3}, IL1B (interleukin 1 beta) [NCBI Gene 3553] {aka IL-1, IL1-BETA, IL1F2, IL1beta}, HLA-C (major histocompatibility complex, class I, C) [NCBI Gene 3107] {aka D6S204, HLA-JY3, HLAC, HLC-C, MHC, PSORS1}, IL18BP (interleukin 18 binding protein) [NCBI Gene 10068] {aka FVH, IL18BPa}, MYD88 (MYD88 innate immune signal transduction adaptor) [NCBI Gene 4615] {aka IMD68, MYD88D, WM1}, IL2 (interleukin 2) [NCBI Gene 3558] {aka IL-2, TCGF, lymphokine}, Akt1 (Akt serine/threonine kinase 1) [NCBI Gene 11651] {aka Akt, LTR-akt, PKB, PKB/Akt, PKBalpha, Rac}, PIK3CB (phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta) [NCBI Gene 5291] {aka P110BETA, PI3K, PI3KBETA, PIK3C1}, JUNB (JunB proto-oncogene, AP-1 transcription factor subunit) [NCBI Gene 3726] {aka AP-1}, TRAF6 (TNF receptor associated factor 6) [NCBI Gene 7189] {aka MGC:3310, RNF85}, IL4 (interleukin 4) [NCBI Gene 3565] {aka BCGF-1, BCGF1, BSF-1, BSF1, IL-4}, IFNG (interferon gamma) [NCBI Gene 3458] {aka IFG, IFI, IMD69}, GZMB (granzyme B) [NCBI Gene 3002] {aka C11, CCPI, CGL-1, CGL1, CSP-B, CSPB}, IL18 (interleukin 18) [NCBI Gene 397057] {aka IL-18}, CTLA4 (cytotoxic T-lymphocyte associated protein 4) [NCBI Gene 1493] {aka ALPS5, CD, CD152, CELIAC3, CTLA-4, GRD4}, KLRK1 (killer cell lectin like receptor K1) [NCBI Gene 22914] {aka CD314, D12S2489E, KLR, NKG2-D, NKG2D}, NLRP3 (NLR family pyrin domain containing 3) [NCBI Gene 114548] {aka AGTAVPRL, AII, AVP, C1orf7, CIAS1, CLR1.1}, IL18BP (interleukin 18 binding protein) [NCBI Gene 100525765], MAPK8 (mitogen-activated protein kinase 8) [NCBI Gene 5599] {aka JNK, JNK-46, JNK1, JNK1A2, JNK21B1/2, PRKM8}, MAPK1 (mitogen-activated protein kinase 1) [NCBI Gene 5594] {aka ERK, ERK-2, ERK2, ERT1, MAPK2, NS13}, IL6 (interleukin 6) [NCBI Gene 3569] {aka BSF-2, BSF2, CDF, HGF, HSF, IFN-beta-2}, MMP9 (matrix metallopeptidase 9) [NCBI Gene 4318] {aka CLG4B, GELB, MANDP2, MMP-9}, CD69 (CD69 molecule) [NCBI Gene 969] {aka AIM, BL-AC/P26, CLEC2C, EA1, GP32/28, MLR-3}, IL18RAP (interleukin 18 receptor accessory protein) [NCBI Gene 8807] {aka ACPL, CD218b, CDw218b, IL-18R-beta, IL-18RAcP, IL-18Rbeta}, CSF2 (colony stimulating factor 2) [NCBI Gene 1437] {aka CSF, GMCSF}, IRAK1 (interleukin 1 receptor associated kinase 1) [NCBI Gene 3654] {aka IRAK, pelle}, CD274 (CD274 molecule) [NCBI Gene 574058] {aka PDL1}, CASP1 (caspase 1) [NCBI Gene 834] {aka ICE, IL1BC, P45}
- **Diseases:** cerebral edema (MESH:D001929), multiple organ failure (MESH:D009102), autoimmune diseases (MESH:D001327), head and neck squamous cell carcinoma (MESH:D000077195), seizures (MESH:D012640), hypotension (MESH:D007022), neurological (MESH:D009461), fever (MESH:D005334), hemophagocytic lymphohistiocytosis (MESH:D051359), pancreatic cancer (MESH:D010190), osteosarcoma (MESH:D012516), headache (MESH:D006261), inflammatory (MESH:D007249), injury to (MESH:D014947), melanoma (MESH:D008545), glioma (MESH:D005910), neuroinflammation (MESH:D000090862), Neurotoxicity (MESH:D020258), hepatosplenomegaly (MESH:C535727), Tumor (MESH:D009369), abnormal liver function (MESH:D056486), liver dysfunction (MESH:D017093), myalgia (MESH:D063806), CRS (MESH:D000080424), breast cancer (MESH:D001943), multi-organ damage (MESH:D000092124), lymph node metastasis (MESH:D008207), tissue damage (MESH:D017695), cognitive decline (MESH:D003072), brain tumor (MESH:D001932), hepatocellular carcinoma (MESH:D006528), esophageal cancer (MESH:D004938), cytopenia (MESH:D006402), colon cancer (MESH:D015179), autoimmune hemolytic anemia (MESH:D000744), abnormal liver and kidney function (MESH:D000014), liver metastasis (MESH:D009362), cytotoxicity (MESH:D064420), MAS (MESH:D055501), capillary leak syndrome (MESH:D019559), dehydration (MESH:D003681), MDSCs (OMIM:601308)
- **Chemicals:** tocilizumab (MESH:C502936), lactate (MESH:D019344), lipid (MESH:D008055), beta-triclane (-), fatty acid (MESH:D005227), temozolomide (MESH:D000077204)
- **Species:** Mus musculus (house mouse, species) [taxon 10090], Homo sapiens (human, species) [taxon 9606]
- **Cell lines:** K7M2 — Mus musculus (Mouse), Hybridoma (CVCL_9202)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12938987/full.md

## Figures

3 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12938987/full.md

## References

93 references — full list in the complete paper: https://tomesphere.com/paper/PMC12938987/full.md

---
Source: https://tomesphere.com/paper/PMC12938987